Key result
Romidepsin demonstrates an acceptable cardiac safety profile in T-cell lymphoma, with clinically insignificant QTc changes primarily linked to concomitant antiemetic use and transient heart rate increases.
Why the study?
What are the cardiac safety concerns and nursing implications for patients receiving romidepsin for T-cell lymphoma?
What are the cardiac safety concerns and nursing implications for patients receiving romidepsin for T-cell lymphoma?
Nurses play a critical role in mitigating cardiac risks during romidepsin treatment by ensuring consistent electrolyte supplementation, appropriate antiemetic selection, and heart rate monitoring.
Answers are grounded in this paper and cite their sources.
Supports romidepsin cardiac safety in T-cell lymphoma; leaves open prospective validation of antiemetic and electrolyte strategies.
PURPOSE/OBJECTIVES: To provide information to help nurses mitigate cardiac risks among patients receiving romidepsin (Istodax®), a histone deacetylase (HDAC) inhibitor approved by the U.S. Food and Drug Administration for the treatment of relapsed/refractory cutaneous and peripheral T-cell lymphoma. . DATA SOURCES: Clinical studies of romidepsin represented the primary data sources. Supporting references included class information on HDAC inhibitors, as well as data regarding the impact of electrolyte imbalances and antiemetic treatment on electrocardiogram (ECG) data. . DATA SYNTHESIS: Cardiac concerns during treatment with romidepsin are multifactorial. Electrolyte deficiencies, which are associated with ECG abnormalities and dysrhythmias, are common among patients with T-cell lymphoma. In addition, clinically insignificant changes in the corrected QT interval reported with romidepsin are primarily attributable to concomitant use of prophylactic antiemetics and likely exaggerated by transient increases in heart rate. . CONCLUSIONS: Data support the cardiac safety of romidepsin while cautioning about the need for nurses' vigilance regarding consistent electrolyte supplementation, appropriate antiemetic selection, and heart rate monitoring. . IMPLICATIONS FOR NURSING: By recognizing drug-related and non-drug-related influences on cardiac safety during treatment with romidepsin, as well as other anticancer agents, nurses can identify risks, report them, and recommend appropriate interventions, which, ultimately, facilitates improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Hronek et al. (2016) conducted a review in Relapsed/refractory cutaneous and peripheral T-cell lymphoma. Romidepsin was evaluated on Cardiac safety and ECG abnormalities. Romidepsin demonstrates an acceptable cardiac safety profile in T-cell lymphoma, with clinically insignificant QTc changes primarily linked to concomitant antiemetic use and transient heart rate increases.
Synapse has enriched 10 related papers. Consider them for comparative context: